What difference does it make? The calculation of QALY gains from health profiles using patient and general population values

Health Policy

Volumn 84, Issue 2-3, 2007, Pages 321-331

  McNamee, Paul ^a  

^a Institute of Applied Health Sciences   (United Kingdom)

Author keywords

Cost benefit analysis; Health policy; Patients; Quality of life; Quality Adjusted Life Years; Social values

Indexed keywords

ADULT; ARTICLE; CALCULATION; CONTROLLED STUDY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; POPULATION RESEARCH; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

COST-BENEFIT ANALYSIS; HEALTH POLICY; HEALTH STATUS; HEALTH SURVEYS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PATIENTS; PLACEBO EFFECT; QUALITY-ADJUSTED LIFE YEARS; SOCIAL VALUES;

EID: 35448988425     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2007.05.004     Document Type: Article

References (24)

1. Miyamoto J.M. Quality adjusted life years (QALY) utility models under expected utility and rank dependent utility assumptions. Journal of Mathematical Psychology 43 (1999) 201-237
2. Mehrez A., and Gafni A. Quality adjusted life years, utility theory and healthy years equivalents. Medical Decision Making 9 (1989) 142-149
3. Broome J. QALYs. Journal of Public Economics 50 (1993) 149-167
4. Gafni A., and Birch S. Preferences for outcomes in economic evaluation: an economic approach to addressing economic problems. Social Science and Medicine 40 (1995) 767-776
5. Fischer G.W. Utility models for multiple objective decisions: do they accurately represent human preferences?. Decision Science 10 (1979) 451-479
6. Johannesson M. QALYs, HYEs and individual preferences-a graphical illustration. Social Science and Medicine 39 (1994) 1623-1632
7. Loewenstein G.F., and Prelec D. Preferences for sequences of outcomes. Psychological Review 100 (1993) 91-108
8. Bleichrodt H., and Johannesson M. The validity of QALYs: an experimental test of constant proportional tradeoff and utility independence. Medical Decision Making 17 (1996) 21-32
9. Krabbe P.F.M., and Bonsel G.J. Sequence effects, health profiles and the QALY model: in search of realistic modeling. Medical Decision Making 18 (1998) 178-186
10. Spencer A. A test of the QALY model when health varies over time. Social Science and Medicine 57 (2003) 1697-1706
11. Tversky A., and Kahneman D. The framing of decisions and the psychology of choice. Science 211 (1981) 453-458
12. Richardson J., Hall J., and Salkeld G. The measurement of utility in multiphase health states. International Journal of Technology Assessment in Health Care 12 (1996) 151-162
13. Kupperman M., Shiboski S., Feeny D., et al. Can preference scores for discrete states be used to derive preference scores for an entire path of events? An application to prenatal diagnosis. Medical Decision Making 17 (1997) 42-55
14. MacKeigan L., O'Brien B., and Oh P. Holistic versus composite preferences for lifetime treatment sequences for type 2 diabetes. Medical Decision Making 19 (1999) 113-121
15. National Institute for Clinical Excellence. Guide to the methods of technology appraisal (2004), National Institute for Clinical Excellence, London
16. Roberts J., and Dolan P. To what extent do people prefer health states with higher values? A note on evidence from the EQ-5D valuation set. Health Economics 13 (2004) 733-737
17. Parkin D., Jacoby A., McNamee P., et al. Treatment of multiple sclerosis with interferon ß: an appraisal of cost-effectiveness and quality of life. Journal of Neurology Neurosurgery and Psychiatry 68 (2000) 144-149
18. The IFNB Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 45 (1995) 1277-1285
19. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
20. Dolan P., Gudex C., Kind P., and Williams A. A social tariff for EuroQoL: results from a UK general population survey (1995), Centre for Health Economics, University of York
21. Weinshenker B.G., Bass B., Rice G.P.A., et al. The natural history of multiple sclerosis: a geographically based study. ii. Predictive value of the early clinical course. Brain 112 (1989) 1419-1428
22. Locadia M., Stalmeier P., Oort F., et al. A comparision of three valuation methods for temporary health states in patients treated with oral anticoagulants. Medical Decision Making 24 (2004) 625-633
23. Lalonde L., Clarke A., Joseph L., et al. Conventional and chained standard gambles in the assessment of coronary heart disease prevention and treatment. Medical Decision Making 19 (1999) 149-156
24. Tsuchiya A., and Dolan P. The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature. Medical Decision Making 25 (2005) 460-467